Please enable JavaScript or talk to your local administrator to get JavaScript enabled.



Funder: National Cancer Institute

Funding period
Funding amount
We have recently found that urine from patients with transitional cell carcinoma of the bladder and renal cell carcinoma stimulate significantly greater migration of capillary and endothelial Balb 3T3 cells than urine from either normal individuals, patients with benign diseases or patients who have had their tumors removed. Our aim is to further investigate this phenomenon and determine if this property in urine can be used to detect new and recurrent bladder and kidney tumors. We plan to determine what factors upset the level of cell migration and what can be done to standardize the assay. We will also compare this assay with urinary cytology to determine the potential usefulness as a screening test in high risk patients. We plan to further characterize and begin to purify the substance in urine responsible for this observation, because the long term objective of this work is to develop a new, noninvasive test for bladder and kidney tumors that can be used on a widespread basis. Such a test would result in better management of patients with these diseases.
Similar projects All >
Sorted by: Start Date
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2020 - 2021
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021



    1103 Clinical Sciences

  • RCDC


  • RCDC

    Clinical Research

  • RCDC

    Kidney Disease

  • RCDC

    Urologic Diseases


    Renal and Urogenital

  • Health Research Areas


  • Broad Research Areas

    Clinical Medicine and Science